Tocagen (NASDAQ:TOCA) posted its quarterly earnings data on Thursday. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.22, Morningstar.com reports. The company had revenue of $18.01 million for the quarter, compared to analyst estimates of $2.01 million. Tocagen had a negative net margin of 130,944.75% and a negative return on equity of 77.46%.

Shares of NASDAQ:TOCA traded up $0.78 during midday trading on Friday, reaching $13.08. The company had a trading volume of 184,495 shares, compared to its average volume of 165,769. The company has a current ratio of 6.06, a quick ratio of 6.06 and a debt-to-equity ratio of 0.56. The firm has a market cap of $240.61 million, a PE ratio of -4.92 and a beta of 2.84. Tocagen has a one year low of $7.52 and a one year high of $15.80.

Several large investors have recently modified their holdings of TOCA. BlackRock Inc. increased its stake in shares of Tocagen by 25.2% in the third quarter. BlackRock Inc. now owns 1,413,285 shares of the company’s stock worth $22,033,000 after buying an additional 284,518 shares during the last quarter. 683 Capital Management LLC bought a new stake in shares of Tocagen in the second quarter worth $467,000. Russell Investments Group Ltd. increased its stake in shares of Tocagen by 107.4% in the first quarter. Russell Investments Group Ltd. now owns 81,067 shares of the company’s stock worth $961,000 after buying an additional 41,978 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Tocagen in the first quarter worth $402,000. Finally, First Republic Investment Management Inc. bought a new stake in shares of Tocagen in the second quarter worth $170,000. Institutional investors and hedge funds own 28.00% of the company’s stock.

A number of research firms have recently issued reports on TOCA. ValuEngine upgraded shares of Tocagen from a “hold” rating to a “buy” rating in a research note on Thursday, September 27th. BidaskClub upgraded shares of Tocagen from a “hold” rating to a “buy” rating in a research note on Saturday, September 22nd. Zacks Investment Research upgraded shares of Tocagen from a “sell” rating to a “hold” rating in a research note on Saturday. B. Riley lifted their price objective on shares of Tocagen from $15.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, September 20th. Finally, Citigroup assumed coverage on shares of Tocagen in a research note on Tuesday, September 4th. They set a “buy” rating and a $27.00 price objective on the stock. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $20.75.

COPYRIGHT VIOLATION WARNING: “Tocagen (TOCA) Posts Earnings Results, Beats Expectations By $0.22 EPS” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://theolympiareport.com/2018/11/10/tocagen-toca-posts-earnings-results-beats-expectations-by-0-22-eps.html.

Tocagen Company Profile

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

Further Reading: Market Capitalization in the Stock Market

Earnings History for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.